NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
75 hedge funds and large institutions have $55.1M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 30 reducing their positions, and 23 closing their positions.
56% more capital invested
Capital invested by funds: $35.5M → $55.1M (+$19.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 83 → 75 (-8)
35% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 23
50% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Trium Capital
London,
United Kingdom
|
+$1.45M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$1.21M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$535K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$401K |
| 5 |
N
Natixis
Paris,
France
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.05M |
| 2 |
Millennium Management
New York
|
-$1.77M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.15M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$787K |
| 5 |
Two Sigma Investments
New York
|
-$686K |
NGM Hedge Fund Activity: Q1 2024 in Review
75 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2024, worth a combined $55.1M — up 56% from $35.5M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of NGM and 15 opened new positions — a net loss of 8 holders — while 30 trimmed existing stakes and 15 added.
The largest buyer was Trium Capital, opening a new position worth an estimated $1.45M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.05M sold.
- 75 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2024, down from 83 in Q4 2023.
- Funds reported $55.1M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2024, up 56% quarter-over-quarter.
- 15 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2024 and 23 closed out, a net change of -8 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Trium Capital, an estimated $1.45M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2024 was EcoR1 Capital, an estimated $2.05M sold.
Based on aggregated 13F filings for Q1 2024.